Soleno Therapeutics Inc (NASDAQ: SLNO) kicked off on Tuesday, up 4.66% from the previous trading day, before settling in for the closing price of $66.51. Over the past 52 weeks, SLNO has traded in a range of $41.50-$90.32.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 20.19% over the last five years. While this was happening, its average annual earnings per share was recorded 84.36%. With a float of $45.97 million, this company’s outstanding shares have now reached $50.44 million.
Soleno Therapeutics Inc (SLNO) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Soleno Therapeutics Inc is 13.50%, while institutional ownership is 96.48%. The most recent insider transaction that took place on Aug 11 ’25, was worth 110,696,581. Before that another transaction happened on Jul 01 ’25, when Company’s insider sold 3,830 for $82.76, making the entire transaction worth $316,971. This insider now owns 13,206 shares in total.
Soleno Therapeutics Inc (SLNO) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -1.83 earnings per share (EPS), lower than consensus estimate (set at -0.61) by -1.22. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.2 per share during the current fiscal year.
Soleno Therapeutics Inc (NASDAQ: SLNO) Trading Performance Indicators
Take a look at Soleno Therapeutics Inc’s (SLNO) current performance indicators. Last quarter, stock had a quick ratio of 15.01. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 113.27.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.15, a number that is poised to hit 0.05 in the next quarter and is forecasted to reach 3.01 in one year’s time.
Technical Analysis of Soleno Therapeutics Inc (SLNO)
Analysing the last 5-days average volume posted by the [Soleno Therapeutics Inc, SLNO], we can find that recorded value of 1.23 million was better than the volume posted last year of 1.13 million. As of the previous 9 days, the stock’s Stochastic %D was 23.81%.
During the past 100 days, Soleno Therapeutics Inc’s (SLNO) raw stochastic average was set at 37.83%, which indicates a significant increase from 25.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 3.87 in the past 14 days, which was higher than the 3.30 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $81.35, while its 200-day Moving Average is $63.73. Now, the first resistance to watch is $70.76. This is followed by the second major resistance level at $71.90. The third major resistance level sits at $73.99. If the price goes on to break the first support level at $67.53, it is likely to go to the next support level at $65.44. Should the price break the second support level, the third support level stands at $64.30.
Soleno Therapeutics Inc (NASDAQ: SLNO) Key Stats
The company with the Market Capitalisation of 3.70 billion has total of 53,145K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -175,850 K annual income. Company’s last quarter sales were recorded 32,660 K and last quarter income was -4,710 K.
